Results 111 to 120 of about 291 (138)

Novel Biomarkers in Hepatocellular Carcinoma from Embryogenic Antigens to cfDNA. [PDF]

Biomedicines
Ghantus R, Ciocan RA, Schlanger D, Popa C, Gherman CD, Vaida C, Gherman B, Pîslă D, Al Hajjar N, Ciocan A.   +9 more
europepmc   +1 more source

Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. [PDF]

Sci Adv
Hruban C, Bruhm DC, Chen IM, Koul S, Annapragada AV, Vulpescu NA, Short S, Theile S, Boyapati K, Alipanahi B, Skidmore ZL, Leal A, Cristiano S, Adleff V, Johannsen JS, Scharpf RB, Foda ZH, Phallen J, Velculescu VE.   +18 more
europepmc   +1 more source

Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors. [PDF]

Cancer Discov
Stutheit-Zhao EY, Sanz-Garcia E, Liu ZA, Wong D, Marsh K, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, Lheureux S, Torti D, Lam B, Yang SYC, Burgener J, Luo P, Zeng Y, Cheng N, Awadalla P, Bratman SV, Ohashi PS, Pugh TJ, Siu LL.   +21 more
europepmc   +1 more source

Upfront blood microRNA test in LDCT-reluctant individuals: insights from the biomild trial. [PDF]

J Exp Clin Cancer Res
Sozzi G, Sabia F, Rolli L, Segale M, Suatoni P, Zanghi A, Ruggirello M, Marchianò A, Boeri M, Pastorino U.   +9 more
europepmc   +1 more source

Advances in translational lung cancer research in 2025: a narrative review. [PDF]

Transl Lung Cancer Res
Xu Y, Kuang Y, Guo Y, Lou Y.
europepmc   +1 more source

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment Response. [PDF]

Med Sci Monit
Parums DV.
europepmc   +1 more source

A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles

Molecular and Cellular Probes, 2022
Early detection is critical for minimizing mortality from cancer. Plasma cell-free DNA (cfDNA) contains the signatures of tumor DNA, allowing us to quantify the signature and diagnose early-stage tumors.
Hyun Ju Cho
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Science, 2021
Enhancing liquid biopsies Liquid biopsies, analyses of cell-free DNA that circulates in the blood, can be used in prenatal testing, oncology, and to monitor organ transplant recipients. Lo et al. review the nongenetic information that can be gleaned from analyses of cell-free DNA, which offers additional ...
Y. M. Dennis Lo, Diana S. C. Han, Peiyong Jiang, Rossa W. K. Chiu   +3 more
openaire   +2 more sources

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology, 2023
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment.
K T, Helzer, M N, Sharifi, J M, Sperger, Y, Shi, M, Annala, M L, Bootsma, S R, Reese, A, Taylor, K R, Kaufmann, H K, Krause, J L, Schehr, N, Sethakorn, D, Kosoff, C, Kyriakopoulos, M E, Burkard, N R, Rydzewski, M, Yu, P M, Harari, M, Bassetti, G, Blitzer, J, Floberg, M, Sjöström, D A, Quigley, S M, Dehm, A J, Armstrong, H, Beltran, R R, McKay, F Y, Feng, R, O'Regan, K B, Wisinski, H, Emamekhoo, A W, Wyatt, J M, Lang, S G, Zhao   +33 more
openaire   +2 more sources